DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) and Insmed (NASDAQ:INSM – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.
Institutional & Insider Ownership
10.1% of DiaMedica Therapeutics shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and price targets for DiaMedica Therapeutics and Insmed, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DiaMedica Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
| Insmed | 1 | 0 | 22 | 2 | 3.00 |
Earnings & Valuation
This table compares DiaMedica Therapeutics and Insmed”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DiaMedica Therapeutics | N/A | N/A | -$32.77 million | ($0.72) | -9.24 |
| Insmed | $606.42 million | 45.50 | -$1.28 billion | ($4.11) | -30.74 |
DiaMedica Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares DiaMedica Therapeutics and Insmed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DiaMedica Therapeutics | N/A | -77.76% | -69.43% |
| Insmed | -76.94% | -123.94% | -44.30% |
Risk and Volatility
DiaMedica Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
Summary
DiaMedica Therapeutics beats Insmed on 9 of the 14 factors compared between the two stocks.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
